Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration

International Journal of Cardiology

Volumn 170, Issue 1, 2013, Pages 30-35

  Webster, Ruth ^a   Patel, Anushka ^a,b   Billot, Laurent ^a   Cass, Alan ^a,c   Burch, Carol ^a   Neal, Bruce ^a   Usherwood, Tim ^d   Thom, Simon ^e   Poulter, Neil ^e   Stanton, Alice ^f   Bots, Michiel L ^g   Grobbee, Diederick E ^g   Prabhakaran, Dorairaj ^h   Reddy, K Srinath ⁱ   Field, Jane ^e   Bullen, Chris ^j   Elley, C Raina ^j   Selak, Vanessa ^j   Rafter, Natasha ^j   Wadham, Angela ^j   Berwanger, Otavio ^k   Rodgers, Anthony ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Faculty of Medicine   (Ireland)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h CENTRE FOR CHRONIC DISEASE CONTROL   (India)

ⁱ PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^j UNIVERSITY OF AUCKLAND   (New Zealand)

^k Hospital do Coração Associação do Sanatório Sírio   (Brazil)

more..

Author keywords

Cardiovascular disease; Meta analysis; Polypill; Prospective

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INCOME; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SYSTOLIC BLOOD PRESSURE;

CARDIOVASCULAR DISEASE; META-ANALYSIS; POLYPILL; PROSPECTIVE;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COOPERATIVE BEHAVIOR; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84888003452     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.10.007     Document Type: Article

References (37)

1. World Health Organization Adherence to long-term therapies: evidence for action 2003 World Health Organization Geneva
2. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Br Med J 324 2002 71 86
3. Blood Pressure Lowering Treatment Trialists Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
4. Cholesterol Treatment Trialists Collaboration C. Baigent, and A. Keech Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
5. K. Kotseva, D. Wood, and G. De Backer Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
6. A. Kumar, G.C. Fonarow, and K.A. Eagle Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH registry Crit Pathw Cardiol 8 2009 104 111
7. R.J. Webster, E.L. Heeley, and D.P. Peiris Gaps in cardiovascular disease risk management in Australian general practice Med J Aust 191 2009 324 329
8. S. Mendis, D. Abegunde, and S. Yusuf WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) Bull World Health Organ 83 2005 820 829
9. K.K. Sharma, R. Gupta, and A. Agrawal Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India Vasc Health Risk Manag 5 2009 1007 1014
10. S. Yusuf, S. Islam, and C.K. Chow Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 2011 1231 1243
11. J.E. Bailey, M.D. Lee, G.W. Somes, and R.L. Graham Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care Clin Ther 18 1996 1252 1262
12. I. Barat, F. Andreasen, and E.M.S. Damsgaard Drug therapy in the elderly: what doctors believe and patients actually do Br J Clin Pharmacol 51 2001 615 622
13. N.H. Miller, M. Hill, T. Kottke, and I.S. Ockene The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals Circulation 95 1997 1085 1090
14. A.H. Paes, A. Bakker, and C.J. Soe-Agnie Impact of dosage frequency on patient compliance Diabetes Care 20 1997 1512 1517
15. E. Shaw, J.G. Anderson, and M. Maloney Factors associated with noncompliance of patients taking antihypertensive medications Hosp Pharm 30 1995 201 203
16. World Health Organization Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions World Health Organization-Wellcome Trust meeting report 2002 [Geneva]
17. S. Yusuf Two decades of progress in preventing vascular disease Lancet 360 2002 2 3
18. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% Br Med J 326 2003 1419
19. S. Indian Polycap, S. Yusuf, and P. Pais Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial [see comment] Lancet 373 2009 1341 1351
20. Pill Collaborative Group A. Rodgers, and A. Patel An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857
21. C.R. Elley, A.K. Gupta, and R. Webster The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials PLoS One 7 2012 [e52145-e52145]
22. M.C. Simmonds, J.P. Higgins, and L.A. Stewart Meta-analysis of individual patient data from randomized trials: a review of methods used in practice Clin Trials 2 2005 209 217
23. S. Thom, J. Field, and N. Poulter Use of a Multidrug Pill in Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe Eur J Prev Cardiol 4th October, 2012 10.1177/2047487312463278
24. H.M. Liu, A. Patel, and A. Brown Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk BMC Public Health 10 2010 458
25. V. Selak, C.R. Elley, and S. Crengle Improving adherence using combination therapy (IMPACT): design and protocol of a randomised controlled trial in primary care Contemp Clin Trials 32 2011 909 915
26. New Zealand Guidelines Group New Zealand cardiovascular guidelines handbook: a summary resource for primary care practitioners 2nd ed. 2005 New Zealand Guidelines Group Wellington
27. G.Y. Zou A modified Poisson regression approach to prospective studies with binary data Am J Epidemiol 159 2004 702 706
28. European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority 2000
29. S. MacMahon, R. Peto, and J. Cutler Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias [see comment] Lancet 335 1990 765 774
30. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
31. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
32. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
33. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
34. A. Pandya, M.C. Weinstein, and T.A. Gaziano A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population PLoS One 6 2011 e20416
35. J.K. Iglehart Prioritizing comparative-effectiveness research - IOM recommendations N Engl J Med 361 2009 325 328
36. Mayo E. Hawthorne, and The Western Electric Company The social problems of an industrial civilization 1945 Division of Research, Graduate School of Business Administration Boston xvii [150 pp.]
37. A.J. Kerr, J. Broad, and S. Wells Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 95 2009 125 129